Business
Viatris Announces 9% Dividend Increase, Fourth Consecutive Quarterly Dividend
PITTSBURGH, Jan. 6, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on Tuesday, January 4, its Board of Directors approved a 9% increase
About this update from Viatris Inc.
[{"type":"text","content":"PITTSBURGH, Jan. 6, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that on Tuesday, January 4, its Board of Directors approved a 9% increase in its quarterly dividend and declared a dividend for the first quarter of 2022 of 12 cents ($0.12) per share on outstanding common stock. At this quarterly dividend rate, subject to the normal quarterly review by the Board of Directors, the annual dividend rate for the fiscal year 2022 is 48 cents ($0.48) per share.\n\n \n \n \n \n \n \n\n \nThe dividend will be payable on March 16, 2022 to shareholders of record at the close of business on February 24, 2022. \n\"We have been pleased with our strong underlying business performance and operational momentum and remain committed to returning capital to shareholders,\" said Michael Goettler, Chief Executive Officer of Viatris. \nAbout Viatris Viatris Inc. (NASDAQ: VTRS) is a new kind of healthcare company, empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars, and a variety of over-the-counter consumer products. With a global workforce of approximately 38,000, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Pennsylvania, Shanghai, China, and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube. \nForward Looking Statement This press release includes statements that constitute \"forward-looking statements.\" These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking stat...